Enveric Biosciences to Participate in Upcoming Investor Conferences in October 2021

NAPLES, Fla., Oct. 7, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology treatments by leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in two upcoming October conferences:

• A.G.P.'s Biotech & Specialty Pharma Conference to be held virtually on Wednesday, October 13, 2021.
• KCSA Psychedelics Investor Conference to be held virtually at VirtualInvestorConferences.com from October 13-14, 2021. Dr. Tucker will present live on Wednesday, October 13^th at 11:30 a.m. ET. Register to attend here.

For more information about the conferences, or to schedule a one-on-one meeting with Enveric's management team, please contact your representatives directly, or send an email to A.G.P. at [e-mail] or KCSA Strategic Communications at [e-mail].

About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is an innovative biotechnology company developing a next-generation mental health and oncology treatment clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. Enveric's robust pipeline supports drug development from the clinic to commercialization for millions of patients in need around the world suffering from conditions that include cancer-related distress, PTSD and more. For more information, please visit www.enveric.com.

Investor Contacts
Valter Pinto / Allison Soss
KCSA Strategic Communications
212.896.1254 / 212.896.1267
[e-mail] / [e-mail] 

Media Contacts
Raquel Cona / Joe McIntyre
KCSA Strategic Communications
212.896.1204 / 856.381.8996
[e-mail]  / [e-mail]

View original content:https://www.prnewswire.com/news-releases/enveric-biosciences-to-participate-in-upcoming-investor-conferences-in-october-2021-301394758.html

SOURCE Enveric Biosciences

Copyright 2021 PR Newswire